State of Wyoming Has $412,000 Position in Exelixis, Inc. (NASDAQ:EXEL)

State of Wyoming grew its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 357.4% during the 4th quarter, HoldingsChannel reports. The fund owned 12,360 shares of the biotechnology company’s stock after acquiring an additional 9,658 shares during the period. State of Wyoming’s holdings in Exelixis were worth $412,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of EXEL. MassMutual Private Wealth & Trust FSB raised its holdings in shares of Exelixis by 18.1% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company’s stock worth $63,000 after acquiring an additional 290 shares in the last quarter. Balyasny Asset Management L.P. increased its position in Exelixis by 1.9% in the 4th quarter. Balyasny Asset Management L.P. now owns 17,203 shares of the biotechnology company’s stock worth $573,000 after purchasing an additional 317 shares during the last quarter. Steward Partners Investment Advisory LLC increased its position in Exelixis by 4.9% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 7,050 shares of the biotechnology company’s stock worth $235,000 after purchasing an additional 330 shares during the last quarter. Oregon Public Employees Retirement Fund raised its stake in shares of Exelixis by 0.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 58,159 shares of the biotechnology company’s stock worth $1,937,000 after purchasing an additional 354 shares in the last quarter. Finally, Principal Securities Inc. lifted its holdings in shares of Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 373 shares during the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Exelixis Price Performance

Exelixis stock opened at $44.36 on Wednesday. Exelixis, Inc. has a fifty-two week low of $20.14 and a fifty-two week high of $48.85. The firm has a fifty day moving average price of $37.54 and a two-hundred day moving average price of $35.97. The firm has a market cap of $12.10 billion, a price-to-earnings ratio of 25.06, a P/E/G ratio of 1.13 and a beta of 0.25.

Insider Transactions at Exelixis

In other Exelixis news, EVP Patrick J. Haley sold 52,636 shares of the firm’s stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $36.98, for a total value of $1,946,479.28. Following the sale, the executive vice president now owns 303,310 shares of the company’s stock, valued at $11,216,403.80. This trade represents a 14.79% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CMO Amy C. Peterson sold 72,776 shares of the company’s stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $45.47, for a total value of $3,309,124.72. Following the transaction, the chief marketing officer now owns 465,393 shares of the company’s stock, valued at approximately $21,161,419.71. This trade represents a 13.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 520,942 shares of company stock worth $22,930,002. Company insiders own 2.82% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Wells Fargo & Company reissued a “market outperform” rating on shares of Exelixis in a research note on Thursday, April 17th. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Exelixis in a research report on Thursday, March 27th. Morgan Stanley restated an “overweight” rating and set a $47.00 price target (up previously from $40.00) on shares of Exelixis in a research note on Wednesday, May 14th. Piper Sandler raised their price target on shares of Exelixis from $37.00 to $38.00 and gave the company an “overweight” rating in a report on Wednesday, February 12th. Finally, StockNews.com lowered shares of Exelixis from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 15th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $38.94.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.